The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 27, 2025

Filed:

Jul. 20, 2020
Applicant:

Avedro, Inc., Burlington, MA (US);

Inventors:

Marc D. Friedman, Needham, MA (US);

Pavel Kamaev, Lexington, MA (US);

Martin Joseph Coffey, Buffalo Grove, IL (US);

Rajesh K. Rajpal, McLean, VA (US);

Alexandra Nicklin, Cambridge, MA (US);

Assignee:

Avedro, Inc., Burlington, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 41/00 (2020.01); A61F 9/007 (2006.01); A61K 9/00 (2006.01); A61K 47/18 (2017.01); A61N 5/06 (2006.01); A61P 27/02 (2006.01);
U.S. Cl.
CPC ...
A61K 41/0057 (2013.01); A61F 9/0079 (2013.01); A61K 9/0048 (2013.01); A61K 47/186 (2013.01); A61N 5/062 (2013.01); A61P 27/02 (2018.01); A61N 2005/0661 (2013.01);
Abstract

Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s), analgesic agent(s), tonicity agent(s), or shear-thinning, or viscosity-increasing agent(s). In another example, a method includes applying preparatory formulation(s) to increase a permeability of a corneal epithelium, and applying therapeutic formulation(s) to the epithelium, where the preparatory formulation(s) include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocisteine, and/or erdosteine. In yet another example, a method includes applying therapeutic formulation(s) to a corneal epithelium to deliver the therapeutic formulation(s) to a stroma, and applying enhancement formulation(s) to the epithelium in response to applying the therapeutic formulation(s), where: the enhancement formulation(s) remove the therapeutic formulation(s) from the epithelium; close tight junctions of the epithelium; promote oxidation for the therapeutic agent(s); and/or further deliver the therapeutic formulation(s) to the stroma.


Find Patent Forward Citations

Loading…